Julie J. Miller, M.D., Ph.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Glioma | 21 | 2024 | 3401 | 3.780 |
Why?
|
Isocitrate Dehydrogenase | 19 | 2024 | 871 | 2.600 |
Why?
|
Brain Neoplasms | 15 | 2024 | 8863 | 1.370 |
Why?
|
Central Nervous System Neoplasms | 3 | 2023 | 895 | 1.060 |
Why?
|
Astrocytoma | 2 | 2024 | 790 | 0.690 |
Why?
|
Sirtuins | 1 | 2021 | 323 | 0.620 |
Why?
|
Arginine | 1 | 2021 | 944 | 0.610 |
Why?
|
Mutation | 17 | 2024 | 29786 | 0.540 |
Why?
|
Lymphoma, Non-Hodgkin | 1 | 2022 | 1381 | 0.490 |
Why?
|
Drugs, Investigational | 1 | 2016 | 214 | 0.480 |
Why?
|
Behcet Syndrome | 1 | 2014 | 84 | 0.470 |
Why?
|
F-Box Proteins | 3 | 2007 | 197 | 0.380 |
Why?
|
Glioblastoma | 4 | 2024 | 3481 | 0.380 |
Why?
|
Central Nervous System Diseases | 1 | 2014 | 518 | 0.360 |
Why?
|
Ubiquitin-Protein Ligase Complexes | 3 | 2007 | 168 | 0.350 |
Why?
|
Cancer Vaccines | 1 | 2016 | 1023 | 0.330 |
Why?
|
Methylation | 2 | 2021 | 1106 | 0.320 |
Why?
|
NAD | 3 | 2021 | 593 | 0.310 |
Why?
|
Autoimmunity | 1 | 2014 | 1349 | 0.280 |
Why?
|
Cell Cycle Proteins | 5 | 2018 | 3462 | 0.260 |
Why?
|
Enzyme Inhibitors | 3 | 2023 | 3798 | 0.250 |
Why?
|
Antineoplastic Agents, Alkylating | 2 | 2020 | 627 | 0.250 |
Why?
|
Cell Line, Tumor | 5 | 2019 | 16689 | 0.250 |
Why?
|
Diamines | 1 | 2024 | 59 | 0.240 |
Why?
|
Antineoplastic Agents | 2 | 2016 | 13695 | 0.220 |
Why?
|
DNA Modification Methylases | 2 | 2020 | 206 | 0.220 |
Why?
|
Immunotherapy | 2 | 2022 | 4445 | 0.210 |
Why?
|
DNA Repair Enzymes | 2 | 2020 | 349 | 0.200 |
Why?
|
Neoplasm Recurrence, Local | 1 | 2019 | 9239 | 0.190 |
Why?
|
Hexokinase | 1 | 2020 | 125 | 0.180 |
Why?
|
Glycoside Hydrolases | 1 | 2020 | 133 | 0.180 |
Why?
|
Humans | 39 | 2024 | 744343 | 0.180 |
Why?
|
Sirtuin 1 | 1 | 2021 | 246 | 0.170 |
Why?
|
Transcription Factor RelA | 1 | 2020 | 275 | 0.170 |
Why?
|
Tretinoin | 1 | 2022 | 517 | 0.170 |
Why?
|
Cyanides | 1 | 2018 | 83 | 0.160 |
Why?
|
Promoter Regions, Genetic | 2 | 2020 | 5867 | 0.160 |
Why?
|
Inflammation | 2 | 2014 | 10638 | 0.160 |
Why?
|
Guanidines | 1 | 2018 | 193 | 0.150 |
Why?
|
Oligodendroglioma | 1 | 2019 | 279 | 0.150 |
Why?
|
World Health Organization | 1 | 2023 | 1318 | 0.150 |
Why?
|
Epidural Neoplasms | 1 | 2016 | 24 | 0.150 |
Why?
|
Dystrophin | 1 | 2018 | 285 | 0.150 |
Why?
|
Telomerase | 2 | 2018 | 730 | 0.140 |
Why?
|
Molecular Targeted Therapy | 2 | 2018 | 2727 | 0.140 |
Why?
|
DNA Mismatch Repair | 1 | 2018 | 426 | 0.130 |
Why?
|
Emergencies | 1 | 2022 | 1170 | 0.130 |
Why?
|
Class I Phosphatidylinositol 3-Kinases | 1 | 2019 | 890 | 0.130 |
Why?
|
Dacarbazine | 1 | 2017 | 566 | 0.120 |
Why?
|
Tumor Suppressor Proteins | 3 | 2020 | 2849 | 0.120 |
Why?
|
Radiographic Image Enhancement | 1 | 2018 | 885 | 0.120 |
Why?
|
Consensus | 1 | 2023 | 2959 | 0.110 |
Why?
|
Mice, SCID | 4 | 2020 | 2716 | 0.110 |
Why?
|
Proto-Oncogene Proteins c-myc | 1 | 2018 | 987 | 0.110 |
Why?
|
Drug Resistance, Neoplasm | 2 | 2018 | 5172 | 0.110 |
Why?
|
Pyridines | 1 | 2024 | 2825 | 0.100 |
Why?
|
Lymphoma | 1 | 2020 | 1877 | 0.100 |
Why?
|
Nervous System Diseases | 1 | 2022 | 1622 | 0.100 |
Why?
|
Drug Design | 1 | 2016 | 1076 | 0.100 |
Why?
|
Xenograft Model Antitumor Assays | 4 | 2020 | 3557 | 0.090 |
Why?
|
Gene Deletion | 1 | 2018 | 2751 | 0.090 |
Why?
|
Proto-Oncogene Proteins c-akt | 1 | 2019 | 2503 | 0.090 |
Why?
|
Blood-Brain Barrier | 1 | 2016 | 1017 | 0.090 |
Why?
|
Combined Modality Therapy | 2 | 2019 | 8642 | 0.090 |
Why?
|
TOR Serine-Threonine Kinases | 1 | 2019 | 2109 | 0.090 |
Why?
|
Kidney Diseases, Cystic | 1 | 2011 | 186 | 0.090 |
Why?
|
Stress, Physiological | 1 | 2017 | 1403 | 0.090 |
Why?
|
Meningioma | 1 | 2018 | 1209 | 0.090 |
Why?
|
Meningeal Neoplasms | 1 | 2018 | 1241 | 0.080 |
Why?
|
Phosphatidylinositol 3-Kinases | 1 | 2018 | 2938 | 0.080 |
Why?
|
Radiation Injuries | 1 | 2016 | 1180 | 0.080 |
Why?
|
S-Phase Kinase-Associated Proteins | 2 | 2005 | 90 | 0.080 |
Why?
|
DNA | 1 | 2022 | 7301 | 0.080 |
Why?
|
Maturation-Promoting Factor | 1 | 2007 | 26 | 0.080 |
Why?
|
Proto-Oncogene Proteins c-mos | 1 | 2007 | 17 | 0.080 |
Why?
|
Diagnostic Imaging | 1 | 2022 | 3507 | 0.080 |
Why?
|
Nuclear Matrix-Associated Proteins | 1 | 2007 | 45 | 0.070 |
Why?
|
Anaphase | 1 | 2007 | 120 | 0.070 |
Why?
|
Signal Transduction | 5 | 2020 | 23403 | 0.070 |
Why?
|
Cerebral Amyloid Angiopathy | 1 | 2014 | 859 | 0.070 |
Why?
|
Antigens, Nuclear | 1 | 2007 | 192 | 0.070 |
Why?
|
Amino Acid Motifs | 2 | 2006 | 936 | 0.070 |
Why?
|
Young Adult | 4 | 2020 | 56430 | 0.070 |
Why?
|
Interphase | 1 | 2006 | 226 | 0.070 |
Why?
|
Proto-Oncogene Proteins | 1 | 2018 | 4554 | 0.070 |
Why?
|
Cytokines | 1 | 2021 | 7322 | 0.070 |
Why?
|
Neoplasm Proteins | 1 | 2018 | 3703 | 0.070 |
Why?
|
Cerebrovascular Circulation | 1 | 2016 | 2731 | 0.070 |
Why?
|
Disease Progression | 2 | 2019 | 13284 | 0.070 |
Why?
|
Cullin Proteins | 2 | 2005 | 180 | 0.060 |
Why?
|
Binding, Competitive | 1 | 2006 | 1157 | 0.060 |
Why?
|
Survival Rate | 1 | 2019 | 12788 | 0.060 |
Why?
|
Prognosis | 3 | 2022 | 29063 | 0.060 |
Why?
|
Xenopus Proteins | 1 | 2007 | 433 | 0.060 |
Why?
|
Genotype | 1 | 2018 | 12951 | 0.060 |
Why?
|
Migraine Disorders | 1 | 2016 | 1620 | 0.060 |
Why?
|
HeLa Cells | 2 | 2007 | 3128 | 0.060 |
Why?
|
Adult | 5 | 2023 | 214055 | 0.060 |
Why?
|
Cloning, Molecular | 1 | 2009 | 4320 | 0.060 |
Why?
|
Conserved Sequence | 1 | 2006 | 1202 | 0.050 |
Why?
|
Substrate Specificity | 1 | 2006 | 1801 | 0.050 |
Why?
|
Up-Regulation | 2 | 2024 | 4217 | 0.050 |
Why?
|
Peptide Synthases | 1 | 2002 | 80 | 0.050 |
Why?
|
Cyclin-Dependent Kinases | 1 | 2005 | 671 | 0.050 |
Why?
|
Aged, 80 and over | 4 | 2019 | 57776 | 0.050 |
Why?
|
Animals | 10 | 2020 | 168757 | 0.050 |
Why?
|
Cadherins | 1 | 2006 | 907 | 0.050 |
Why?
|
Protein Binding | 4 | 2007 | 9386 | 0.050 |
Why?
|
Ligases | 1 | 2002 | 333 | 0.050 |
Why?
|
Tumor Microenvironment | 2 | 2024 | 3586 | 0.050 |
Why?
|
Clinical Trials as Topic | 1 | 2016 | 7913 | 0.050 |
Why?
|
Viral Matrix Proteins | 1 | 2020 | 186 | 0.040 |
Why?
|
Brain | 2 | 2023 | 26385 | 0.040 |
Why?
|
Multiprotein Complexes | 1 | 2005 | 1119 | 0.040 |
Why?
|
Sex Chromatin | 1 | 2018 | 20 | 0.040 |
Why?
|
Magnetic Resonance Imaging | 4 | 2018 | 35421 | 0.040 |
Why?
|
Ubiquitin-Protein Ligases | 2 | 2005 | 1861 | 0.040 |
Why?
|
Pteridines | 1 | 2018 | 45 | 0.040 |
Why?
|
Follow-Up Studies | 1 | 2019 | 39050 | 0.040 |
Why?
|
Cell Nucleus | 1 | 2006 | 2969 | 0.040 |
Why?
|
Nicotinamide Phosphoribosyltransferase | 1 | 2017 | 86 | 0.040 |
Why?
|
Glycolysis | 1 | 2020 | 827 | 0.040 |
Why?
|
Microscopy, Electron, Transmission | 1 | 2018 | 712 | 0.030 |
Why?
|
Myeloid Differentiation Factor 88 | 1 | 2020 | 571 | 0.030 |
Why?
|
Female | 10 | 2020 | 380194 | 0.030 |
Why?
|
Aged | 5 | 2019 | 163280 | 0.030 |
Why?
|
Proteomics | 1 | 2009 | 3638 | 0.030 |
Why?
|
Middle Aged | 6 | 2019 | 213383 | 0.030 |
Why?
|
Antigens, CD | 1 | 2006 | 4026 | 0.030 |
Why?
|
Acrylamides | 1 | 2017 | 255 | 0.030 |
Why?
|
Mice | 6 | 2020 | 81183 | 0.030 |
Why?
|
Cell Line | 1 | 2009 | 15997 | 0.030 |
Why?
|
Membrane Proteins | 1 | 2011 | 7880 | 0.030 |
Why?
|
Proteins | 1 | 2009 | 6103 | 0.030 |
Why?
|
Retrospective Studies | 2 | 2019 | 77449 | 0.030 |
Why?
|
Mitosis | 1 | 2018 | 1208 | 0.030 |
Why?
|
Stroke | 1 | 2016 | 9981 | 0.030 |
Why?
|
Protein Structure, Quaternary | 2 | 2005 | 436 | 0.030 |
Why?
|
Vascular Endothelial Growth Factor A | 1 | 2024 | 3508 | 0.030 |
Why?
|
Random Allocation | 1 | 2017 | 2429 | 0.030 |
Why?
|
Tumor Cells, Cultured | 1 | 2020 | 6314 | 0.030 |
Why?
|
Male | 6 | 2019 | 350118 | 0.030 |
Why?
|
Gene Silencing | 1 | 2018 | 1538 | 0.030 |
Why?
|
Mice, Nude | 1 | 2018 | 3689 | 0.030 |
Why?
|
NF-kappa B | 1 | 2020 | 2499 | 0.030 |
Why?
|
Acute Disease | 1 | 2022 | 7149 | 0.020 |
Why?
|
Ciliary Motility Disorders | 1 | 2011 | 47 | 0.020 |
Why?
|
Down-Regulation | 1 | 2018 | 3002 | 0.020 |
Why?
|
Polycystic Kidney Diseases | 1 | 2011 | 133 | 0.020 |
Why?
|
Encephalocele | 1 | 2011 | 136 | 0.020 |
Why?
|
Centrosome | 1 | 2011 | 201 | 0.020 |
Why?
|
NIH 3T3 Cells | 1 | 2011 | 677 | 0.020 |
Why?
|
Neoplasms | 2 | 2016 | 21683 | 0.020 |
Why?
|
Crystallography, X-Ray | 2 | 2005 | 2011 | 0.020 |
Why?
|
Piperidines | 1 | 2017 | 1602 | 0.020 |
Why?
|
DNA Damage | 1 | 2018 | 2432 | 0.020 |
Why?
|
Tumor Suppressor Protein p53 | 1 | 2018 | 2948 | 0.020 |
Why?
|
Kaplan-Meier Estimate | 1 | 2018 | 6538 | 0.020 |
Why?
|
Retinitis Pigmentosa | 1 | 2011 | 386 | 0.020 |
Why?
|
Cyclin B | 1 | 2007 | 108 | 0.020 |
Why?
|
Cilia | 1 | 2011 | 466 | 0.020 |
Why?
|
Dyneins | 1 | 2007 | 123 | 0.020 |
Why?
|
Drug Delivery Systems | 1 | 2018 | 2219 | 0.020 |
Why?
|
T-Lymphocytes, Regulatory | 1 | 2020 | 2988 | 0.020 |
Why?
|
CDC2 Protein Kinase | 1 | 2007 | 220 | 0.020 |
Why?
|
HCT116 Cells | 1 | 2007 | 408 | 0.020 |
Why?
|
Hedgehog Proteins | 1 | 2011 | 783 | 0.020 |
Why?
|
Cohort Studies | 2 | 2018 | 40561 | 0.020 |
Why?
|
Chromosomes, Human | 1 | 2007 | 457 | 0.020 |
Why?
|
Feedback, Physiological | 1 | 2007 | 479 | 0.020 |
Why?
|
Mammals | 1 | 2009 | 1143 | 0.010 |
Why?
|
Sensitivity and Specificity | 1 | 2018 | 14722 | 0.010 |
Why?
|
RNA, Messenger | 1 | 2018 | 13033 | 0.010 |
Why?
|
Treatment Outcome | 2 | 2022 | 63114 | 0.010 |
Why?
|
Cell Proliferation | 1 | 2018 | 10481 | 0.010 |
Why?
|
Amino Acid Sequence | 2 | 2007 | 13815 | 0.010 |
Why?
|
Gene Expression Regulation, Neoplastic | 1 | 2018 | 8428 | 0.010 |
Why?
|
Emergency Service, Hospital | 1 | 2022 | 7659 | 0.010 |
Why?
|
Protein Structure, Secondary | 1 | 2005 | 1246 | 0.010 |
Why?
|
Protein Kinase Inhibitors | 1 | 2018 | 5535 | 0.010 |
Why?
|
Microtubule-Associated Proteins | 1 | 2007 | 1086 | 0.010 |
Why?
|
Oocytes | 1 | 2007 | 1187 | 0.010 |
Why?
|
Molecular Sequence Data | 2 | 2007 | 18111 | 0.010 |
Why?
|
Cross-Sectional Studies | 1 | 2022 | 25043 | 0.010 |
Why?
|
Ubiquitin-Conjugating Enzymes | 1 | 2002 | 195 | 0.010 |
Why?
|
Cyclin-Dependent Kinase Inhibitor p27 | 1 | 2002 | 323 | 0.010 |
Why?
|
SKP Cullin F-Box Protein Ligases | 1 | 2002 | 177 | 0.010 |
Why?
|
DNA-Binding Proteins | 1 | 2018 | 9648 | 0.010 |
Why?
|
Adolescent | 2 | 2018 | 85781 | 0.010 |
Why?
|
Recombinant Fusion Proteins | 1 | 2009 | 3772 | 0.010 |
Why?
|
Ubiquitins | 1 | 2002 | 384 | 0.010 |
Why?
|
Zebrafish | 1 | 2011 | 2994 | 0.010 |
Why?
|
Macromolecular Substances | 1 | 2002 | 1454 | 0.010 |
Why?
|
Cell Division | 1 | 2007 | 4568 | 0.010 |
Why?
|
Nerve Tissue Proteins | 1 | 2011 | 4462 | 0.010 |
Why?
|
Sequence Homology, Amino Acid | 1 | 2002 | 2839 | 0.010 |
Why?
|
Sequence Alignment | 1 | 2002 | 2256 | 0.010 |
Why?
|
Cell Cycle | 1 | 2005 | 2967 | 0.010 |
Why?
|
Ubiquitin | 1 | 2002 | 852 | 0.010 |
Why?
|
Structure-Activity Relationship | 1 | 2002 | 3129 | 0.010 |
Why?
|
Protein Structure, Tertiary | 1 | 2002 | 3846 | 0.010 |
Why?
|
Phosphorylation | 1 | 2005 | 8436 | 0.010 |
Why?
|
Binding Sites | 1 | 2002 | 6114 | 0.010 |
Why?
|
Carrier Proteins | 1 | 2005 | 5021 | 0.010 |
Why?
|
Models, Molecular | 1 | 2002 | 5456 | 0.010 |
Why?
|